

**RESTRICTED
VETERINARY MEDICINE**

Keep out of reach of children
FOR ANIMAL TREATMENT ONLY

Porcilis[®]
PCV M Hyo 200 mL

Emulsion for injection for pigs

2mL by intramuscular injection
PCV ORF2 subunit antigen ≥ 2828 AU
M.hypopneumoniae inac. ≥ 2.69 RPU



SHAKE WELL BEFORE USE.

Use all product within 3 days of opening.

Administer one dose (2 mL) by intramuscular injection in the neck in the area behind the ear, from 3 weeks of age.

Read package leaflet before use.

Open Date:

Discard Date:

Store between 2°C and 8°C (Refrigerate. Do not freeze). Protect from light.

ACVM registration No: A11423.

Registered to
Schering-Plough Animal Health Ltd
33 Whakatiki Street, Upper Hutt
Phone: 0800 800 543
www.msd-animal-health.co.nz



08-03-2018

Batch: Expiry:

Imprint
Area

180364 R4

**RESTRICTED
VETERINARY MEDICINE**

Keep out of reach of children
FOR ANIMAL TREATMENT ONLY

Porcilis[®]
PCV M Hyo 100 mL

Emulsion for injection for pigs

2mL by intramuscular injection
PCV ORF2 subunit antigen ≥ 2828 AU
M.hypopneumoniae inac. ≥ 2.69 RPU



SHAKE WELL BEFORE USE.

Use all product within 3 days of opening.

Administer one dose (2 mL) by intramuscular injection in the neck in the area behind the ear, from 3 weeks of age.

Read package leaflet before use.

Open Date:

Discard Date:

Store between 2°C and 8°C (Refrigerate. Do not freeze). Protect from light.

ACVM registration No: A11423.

Registered to
Schering-Plough Animal Health Ltd
33 Whakatiki Street, Upper Hutt
Phone: 0800 800 543
www.msd-animal-health.co.nz



08-03-2018

Batch: Expiry:

Imprint
Area

181561 R3

RESTRICTED
VETERINARY MEDICINE
Porcilis®
PCV M Hyo
100 mL

181251 R2

Read leaflet before use

For the active immunisation of pigs against PCV2 infection. To reduce PCV2 associated viraemia, virus load in lungs, tonsils and lymphoid tissues. To reduce faecal and nasal virus shedding caused by porcine circovirus type 2 (PCV2) infection, and thereby minimise environmental contamination. To aid in the prevention of enzootic pneumonia of swine caused by *Mycoplasma hyopneumoniae* demonstrated by:

- Reduction of the severity of lung lesions caused by *Mycoplasma hyopneumoniae* infection; and
- Reduction of weight loss associated with infection with *Mycoplasma hyopneumoniae* in the finishing period.



DOSAGE AND ADMINISTRATION

The vaccine is a liquid and ready to use product. Before using the vaccine, allow it to reach room temperature (15-25°C) and shake well before use. Use sterile syringes and needles. Avoid introduction of contamination. Administer one dose (2 mL) by intramuscular injection in the neck in the area behind the ear, from 3 weeks of age.

PCV2:

Onset of immunity: 2 weeks after vaccination.
Duration of immunity: 22 weeks after vaccination.

M. hyopneumoniae:

Onset of immunity: 4 weeks after vaccination.
Duration of immunity: 21 weeks after vaccination

RESTRICTED
VETERINARY MEDICINE
Keep out of reach of children
FOR ANIMAL TREATMENT ONLY

Porcilis®
PCV M Hyo

Emulsion for injection for pigs

50
100 mL



SIDE EFFECTS

Refer to leaflet

USER SAFETY

Take care to avoid self-injection. See leaflet for advice.

WITHHOLDING PERIODS

Zero (0) days

STORAGE

Store at 2 to 8°C. Do not freeze. Protect from direct sunlight. ACVM registration No: A11423. See www.foodsafety.govt.nz for registration conditions.

Registered to
Schering-Plough Animal Health Ltd
33 Whakatiki Street, Upper Hutt
Phone: 0800 800 543
www.msd-animal-health.co.nz



PSA020040 02 R1
47x47x99mm
CMYK

Imprint area
Varnish Free

Batch/Expiry:



08-03-2018



RESTRICTED
VETERINARY MEDICINE
Porcilis®
PCV M Hyo
 200 mL

193295 R3

Read leaflet before use

For the active immunisation of pigs against PCV2 infection. To reduce PCV2 associated viraemia, virus load in lungs, tonsils and lymphoid tissues.

To reduce faecal and nasal virus shedding caused by porcine circovirus type 2 (PCV2) infection, and thereby minimise environmental contamination.

To aid in the prevention of enzootic pneumonia of swine caused by *Mycoplasma hyopneumoniae* demonstrated by:

- Reduction of the severity of lung lesions caused by *Mycoplasma hyopneumoniae* infection; and
- Reduction of weight loss associated with infection with *Mycoplasma hyopneumoniae* in the finishing period.

DOSAGE AND ADMINISTRATION

The vaccine is a liquid and ready to use product. Before using the vaccine, allow it to reach room temperature (15-25°C) and shake well before use. Use sterile syringes and needles. Avoid introduction of contamination.

Administer one dose (2 mL) by intramuscular injection in the neck in the area behind the ear, from 3 weeks of age.

PCV2:

Onset of immunity: 2 weeks after vaccination.

Duration of immunity: 22 weeks after vaccination.

***M. hyopneumoniae*:**

Onset of immunity: 4 weeks after vaccination.

Duration of immunity: 21 weeks after vaccination

RESTRICTED
VETERINARY MEDICINE
 Keep out of reach of children
 FOR ANIMAL TREATMENT ONLY

Porcilis®
PCV M Hyo

Emulsion for injection for pigs

200 mL

SIDE EFFECTS

Refer to leaflet

USER SAFETY

Take care to avoid self-injection. See leaflet for advice.

WITHHOLDING PERIODS

Zero (0) days

STORAGE

Store at 2 to 8°C. Do not freeze. Protect from direct sunlight.

ACVM registration No: A11423. See www.foodsafety.govt.nz for registration conditions.

Registered to

Schering-Plough Animal Health Ltd

33 Whakatiki Street, Upper Hutt

Phone: 0800 800 543

www.msd-animal-health.co.nz



9 415116 043819 >



PSA020236 01 R1
 65x65x114,6mm
 CMYK

imprint area

Varnish Free

Batch/Expiry:



08-03-2018

RESTRICTED VETERINARY MEDICINE

Keep out of reach of children

FOR ANIMAL TREATMENT ONLY**Porcilis[®] PCV M Hyo**

Emulsion for injection for pigs

Each dose of 2 mL contains:

Porcine circovirus type 2 (PCV2) ORF 2 subunit antigen: ≥ 2828 AU¹*Mycoplasma hyopneumoniae* J strain inactivated: ≥ 2.69 RPU²¹ AU: Antigenic units² RPU: Relative potency units

08-03-2018

INDICATIONS

For the active immunisation of pigs against PCV2 infection.

To reduce PCV2 associated viraemia, virus load in lungs, tonsils and lymphoid tissues.

To reduce faecal and nasal virus shedding caused by porcine circovirus type 2 (PCV2) infection, and thereby minimise environmental contamination.

To aid in the prevention of enzootic pneumonia of swine caused by *Mycoplasma hyopneumoniae* demonstrated by:

- Reduction in the severity of lung lesions caused by *Mycoplasma hyopneumoniae* infection:

And

- Reduction of weight loss associated with infection with *Mycoplasma hyopneumoniae* in the finishing period.

PCV2:

Onset of immunity: 2 weeks after vaccination.

Duration of immunity: 22 weeks after vaccination.

Mycoplasma hyopneumoniae:

Onset of immunity: 4 weeks after vaccination.

Duration of immunity: 21 weeks after vaccination.

PORCILIS PCV M HYO is effective in the face of maternally derived antibodies to PCV and/or *Mycoplasma hyopneumoniae*.**DIRECTIONS FOR USE****Shake well before use.**

Use all product within 3 days of opening.

DO NOT mix with any other vaccine or immunobiological product.

PRECAUTIONS

Vaccinate only healthy animals.

Use during pregnancy or lactation has not been determined.

SIDE EFFECTSA transient increase in body temperature very commonly occurs on the day of vaccination (mean ± 1 C, in individual pigs up to 2 C). The animals return to normal from 1 to 2 days after the peak temperature is observed.

Mild systemic reactions may uncommonly be observed up to one day after vaccination.

Affected animals are less active, show a tendency to lie down and display minor signs of discomfort.

Transient local injection site reactions, which are restricted to a slight swelling (<2 cm diameter), may uncommonly occur (in less than 1% of animals) and normally disappear within 1 day. In very rare cases anaphylactic-type reactions can occur. In the event of such reactions, treatment may be needed.

DOSAGE AND ADMINISTRATION

The vaccine is a liquid and ready to use product. Before using the vaccine, allow it to reach room temperature (15-25°C) and shake well before use. Use sterile syringes and needles. Avoid introduction of contamination.

Administer one dose (2 mL) by intramuscular injection in the neck in the area behind the ear, from 3 weeks of age.

DRUG INTERACTIONS

Compatibility studies with concurrent use of other veterinary products were not performed.

WITHHOLDING PERIODS

Zero (0) days

ADDITIONAL USER SAFETY

Take care to avoid self-injection.

This product contains mineral oil. In the event of self-administration, seek prompt medical attention and take this package leaflet/carton with you. Accidental self-administration may result in local bruising, severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the infected finger if prompt medical attention is not given. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

See Safety Data Sheet for further information. www.msd-animal-health.co.nz

DISPOSAL

Dispose of unused contents into an appropriate biohazard container or a suitable landfill. Dispose of empty container by puncturing and burying in a suitable landfill. Do NOT burn.

STORAGE

Store between 2°C and 8°C (Refrigerate. Do not freeze). Protect from light.

ACVM Registration No: A11423

See www.foodsafety.govt.nz for registration conditions.

Porcilis is a registered trademark. © 2017

Registered to

Schering-Plough Animal Health Ltd

33 Whakatiki Street, Upper Hutt

Phone: 0800 800 543

www.msd-animal-health.co.nz



MSD Animal Health

A handwritten signature in blue ink, likely of a representative from MSD Animal Health, positioned below the seal.

08-03-2018